Cargando…

First do no harm

Detalles Bibliográficos
Autores principales:	Huisman, Menno V., Klok, Frederikus A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008415/ https://www.ncbi.nlm.nih.gov/pubmed/35434468 http://dx.doi.org/10.1002/rth2.12694

Ejemplares similares

First do not harm
por: Jamoulle, Marc
Publicado: (2015)

Pharmacological properties of betrixaban
por: Huisman, Menno V, et al.
Publicado: (2018)

Blood transfusion and the lung: first do no harm?
por: Napolitano, Lena M
Publicado: (2011)

Diagnostic Management of Acute Pulmonary Embolism in COVID-19 and Other Special Patient Populations
por: Martens, Emily S. L., et al.
Publicado: (2022)

“ISTH guidelines for antithrombotic treatment in COVID‐19”: Comment from Huisman et al.
por: Huisman, Menno V., et al.
Publicado: (2022)

Procedures in pediatric primary care: first do no harm
por: Freed, Gary L.
Publicado: (2015)

Vaccine-induced immune thrombotic thrombocytopenia
por: Klok, Frederikus A, et al.
Publicado: (2022)

Anticoagulation in splanchnic and cerebral vein thrombosis: Still groping in the dark
por: Klok, Frederikus A., et al.
Publicado: (2020)

Paper reports overview: First do no harm: the aftermath of intensive care
por: Mellor, Adrian
Publicado: (2000)

COVID‐19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance
por: Cannegieter, Suzanne C., et al.
Publicado: (2020)

Comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'
por: Klok, Frederikus A., et al.
Publicado: (2019)

Primum Non Nocere (First, Not to Harm) and Secundus, Opinio Vulnero (Second, Report the Harm)
por: Rivkees, Scott A.
Publicado: (2009)

First, do no harm
por: Marler, Thomas E., et al.
Publicado: (2017)

Pulmonary flow profile and distensibility following acute pulmonary embolism
por: Klok, Frederikus A, et al.
Publicado: (2011)

Computed Tomography Pulmonary Perfusion for Prediction of Short-Term Clinical Outcome in Acute Pulmonary Embolism
por: van Dam, Lisette F., et al.
Publicado: (2021)

Accuracy and reproducibility of CT right-to-left ventricular diameter measurement in patients with acute pulmonary embolism
por: Ende-Verhaar, Yvonne M., et al.
Publicado: (2017)

MRI evaluation of right and left ventricular remodeling and surrogate markers of PH following acute pulmonary embolism
por: Klok, Frederikus A, et al.
Publicado: (2009)

On language – first, do no harm
por: Schumann, Roman
Publicado: (2022)

What is the harm in harmful conception? On threshold harms in non-identity cases
por: Williams, Nicola J., et al.
Publicado: (2014)

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
por: Hendriks, Stephan V., et al.
Publicado: (2020)

Sensitivity of a Simple Noninvasive Screening Algorithm for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism
por: Ende-Verhaar, Yvonne M., et al.
Publicado: (2018)

COVID-19: First Do No Harm
por: Waterer, Grant W., et al.
Publicado: (2020)

Primum non nocere (first do no harm). The SARS-CoV-2 pandemic course in oldest in Italy
por: Cucinotta, Domenico
Publicado: (2020)

Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism
por: Kooiman, Judith, et al.
Publicado: (2015)

Validation and impact of a simplified clinical decision rule for diagnosing pulmonary embolism in primary care: design of the PECAN prospective diagnostic cohort management study
por: van Maanen, Rosanne, et al.
Publicado: (2019)

The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment
por: Kooiman, Judith, et al.
Publicado: (2015)

Diabetes Drug Therapy -- First Do No Harm
por: Curtiss, Frederic R., et al.
Publicado: (2008)

Magnetic Resonance Direct Thrombus Imaging (MRDTI) Can Distinguish Between Old and New Thrombosis in the Abdominal Aorta: a Case Report
por: van Dam, Lisette F, et al.
Publicado: (2020)

The Olympics and harm reduction?
por: Kayser, Bengt, et al.
Publicado: (2012)

Harm reduction in hospitals
por: Sharma, Malika, et al.
Publicado: (2017)

Treatment and prevention of cancer-associated thrombosis in the Netherlands: A national survey
por: Kaptein, Fleur H.J., et al.
Publicado: (2023)

“First do no harm” and the importance of prediction in oncology
por: Characiejus, Dainius, et al.
Publicado: (2010)

Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism
por: van der Wall, Sake J., et al.
Publicado: (2018)

Prescribing cannabis for harm reduction
por: Collen, Mark
Publicado: (2012)

Harm reduction in hospitals: is it time?
por: Rachlis, Beth S, et al.
Publicado: (2009)

Treating self-harm in young people
por: Borschmann, Rohan, et al.
Publicado: (2020)

Drug use and harm reduction in Afghanistan
por: Todd, Catherine S, et al.
Publicado: (2005)

Do Intracerebral Cytokine Responses Explain the Harmful Effects of Dexamethasone in Human Immunodeficiency Virus–associated Cryptococcal Meningitis?
por: Beardsley, Justin, et al.
Publicado: (2019)

Clinical Surveillance vs. Anticoagulation For low-risk patiEnts with isolated SubSegmental Pulmonary Embolism: protocol for a multicentre randomised placebo-controlled non-inferiority trial (SAFE-SSPE)
por: Baumgartner, Christine, et al.
Publicado: (2020)

Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts
por: den Exter, Paul L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4kc80bs9coufaoj0ch92cr6cag